Tempest Therapeutics IncNASDAQ:TPST
- LAST PRICE3.1800
- TODAY'S CHANGE (%)-0.0400 (-1.2422%)
- Bid / Lots3.2000/ 4
- Ask / Lots3.2900/ 152
- Open / Previous Close3.2100 / 3.2200
- Day Range
- 52 Week Range
- Volume317,970
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TPST |
|---|---|---|
| 09:32 ET | 4854 | 3.25 |
| 09:36 ET | 17109 | 3.21 |
| 09:38 ET | 3985 | 3.22 |
| 09:39 ET | 7318 | 3.2163 |
| 09:41 ET | 870 | 3.2021 |
| 09:43 ET | 1626 | 3.21 |
| 09:45 ET | 1200 | 3.22 |
| 09:48 ET | 300 | 3.23 |
| 09:50 ET | 130 | 3.2299 |
| 09:52 ET | 1096 | 3.2299 |
| 09:54 ET | 909 | 3.23 |
| 09:57 ET | 400 | 3.2484 |
| 10:03 ET | 200 | 3.2499 |
| 10:12 ET | 599 | 3.23 |
| 10:15 ET | 200 | 3.24 |
| 10:17 ET | 5409 | 3.24 |
| 10:19 ET | 500 | 3.245 |
| 10:21 ET | 100 | 3.25 |
| 10:24 ET | 163 | 3.25 |
| 10:26 ET | 250 | 3.2398 |
| 10:28 ET | 122 | 3.24 |
| 10:30 ET | 2194 | 3.23 |
| 10:32 ET | 910 | 3.234 |
| 10:33 ET | 9032 | 3.1976 |
| 10:35 ET | 6510 | 3.17 |
| 10:37 ET | 6344 | 3.18 |
| 10:39 ET | 400 | 3.1812 |
| 10:42 ET | 500 | 3.1952 |
| 10:44 ET | 200 | 3.18 |
| 10:46 ET | 100 | 3.2052 |
| 10:48 ET | 900 | 3.21 |
| 10:50 ET | 8546 | 3.23 |
| 10:55 ET | 2365 | 3.23 |
| 10:57 ET | 3900 | 3.22 |
| 11:00 ET | 1597 | 3.23 |
| 11:02 ET | 968 | 3.23 |
| 11:04 ET | 3002 | 3.21 |
| 11:06 ET | 2023 | 3.21 |
| 11:08 ET | 200 | 3.215 |
| 11:15 ET | 7178 | 3.238 |
| 11:18 ET | 9921 | 3.2 |
| 11:20 ET | 500 | 3.22 |
| 11:22 ET | 900 | 3.21 |
| 11:24 ET | 10214 | 3.17 |
| 11:26 ET | 1000 | 3.1674 |
| 11:27 ET | 27714 | 3.145 |
| 11:29 ET | 1881 | 3.13 |
| 11:31 ET | 7231 | 3.12 |
| 11:33 ET | 3199 | 3.14 |
| 11:36 ET | 5577 | 3.1464 |
| 11:38 ET | 8400 | 3.16 |
| 11:40 ET | 400 | 3.16 |
| 11:42 ET | 300 | 3.16 |
| 11:44 ET | 200 | 3.15 |
| 11:45 ET | 500 | 3.15 |
| 11:47 ET | 1252 | 3.17 |
| 11:49 ET | 140 | 3.1799 |
| 11:51 ET | 1000 | 3.1792 |
| 11:56 ET | 400 | 3.18 |
| 11:58 ET | 182 | 3.17 |
| 12:02 ET | 1647 | 3.18 |
| 12:16 ET | 200 | 3.19 |
| 12:20 ET | 100 | 3.2 |
| 12:21 ET | 5422 | 3.185 |
| 12:23 ET | 361 | 3.19 |
| 12:30 ET | 600 | 3.19 |
| 12:34 ET | 100 | 3.2 |
| 12:41 ET | 1333 | 3.1994 |
| 12:43 ET | 16483 | 3.2 |
| 12:45 ET | 7808 | 3.2 |
| 12:48 ET | 228 | 3.22 |
| 12:56 ET | 473 | 3.21 |
| 12:57 ET | 1190 | 3.21 |
| 01:01 ET | 1000 | 3.2176 |
| 01:06 ET | 100 | 3.22 |
| 01:10 ET | 285 | 3.2106 |
| 01:15 ET | 270 | 3.23 |
| 01:17 ET | 831 | 3.2494 |
| 01:19 ET | 100 | 3.24 |
| 01:24 ET | 308 | 3.24 |
| 01:26 ET | 700 | 3.2302 |
| 01:28 ET | 100 | 3.25 |
| 01:30 ET | 1612 | 3.23 |
| 01:48 ET | 100 | 3.23 |
| 01:50 ET | 5875 | 3.19 |
| 01:57 ET | 613 | 3.19 |
| 02:00 ET | 100 | 3.21 |
| 02:02 ET | 5197 | 3.19 |
| 02:04 ET | 100 | 3.18 |
| 02:06 ET | 441 | 3.19 |
| 02:08 ET | 100 | 3.19 |
| 02:13 ET | 100 | 3.19 |
| 02:20 ET | 569 | 3.1977 |
| 02:24 ET | 700 | 3.18 |
| 02:31 ET | 300 | 3.175 |
| 02:36 ET | 100 | 3.18 |
| 02:38 ET | 100 | 3.175 |
| 02:44 ET | 600 | 3.185 |
| 02:45 ET | 6485 | 3.1701 |
| 02:49 ET | 1057 | 3.16 |
| 02:54 ET | 100 | 3.16 |
| 02:56 ET | 5300 | 3.17 |
| 02:58 ET | 769 | 3.17 |
| 03:02 ET | 300 | 3.16 |
| 03:05 ET | 300 | 3.16 |
| 03:07 ET | 2300 | 3.16 |
| 03:09 ET | 473 | 3.1669 |
| 03:12 ET | 159 | 3.16 |
| 03:16 ET | 200 | 3.1634 |
| 03:20 ET | 828 | 3.17 |
| 03:25 ET | 100 | 3.18 |
| 03:27 ET | 535 | 3.17 |
| 03:30 ET | 1100 | 3.18 |
| 03:36 ET | 3785 | 3.1901 |
| 03:38 ET | 100 | 3.1921 |
| 03:39 ET | 1149 | 3.1977 |
| 03:41 ET | 186 | 3.1982 |
| 03:45 ET | 1200 | 3.19 |
| 03:50 ET | 100 | 3.19 |
| 03:52 ET | 1257 | 3.18 |
| 03:54 ET | 5126 | 3.175 |
| 03:56 ET | 100 | 3.17 |
| 03:57 ET | 799 | 3.18 |
May 13, 2024
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 8:14AM ET on Monday May 13, 2024 by Dow Jones
8:14AM ET on Monday May 13, 2024 by Dow Jones
May 10, 2024
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co., from 3:08PM ET on Friday May 10, 2024 by Dow Jones
3:08PM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:29PM ET on Thursday May 09, 2024 by Dow Jones
4:29PM ET on Thursday May 09, 2024 by Dow JonesPress Release: Tempest Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:29PM ET on Thursday May 09, 2024 by Dow Jones
4:29PM ET on Thursday May 09, 2024 by Dow Jones
Apr 26, 2024
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Apr 26, 2024 by Dow Jones
4:05PM ET on Friday Apr 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tempest Therapeutics Inc | 71.5M | -1.8x | --- |
Intensity Therapeutics Inc | 69.9M | -4.4x | --- |
Landos Biopharma Inc | 69.7M | -5.6x | --- |
Tiziana Life Sciences Ltd | 69.6M | -5.0x | --- |
Maia Biotechnology Inc | 68.1M | -2.1x | --- |
Regencell Bioscience Holdings Ltd | 67.8M | -8.9x | --- |
Company Information
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Contact Information
- Headquarters
- 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
- Phone
- 415-798-8589
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Michael Raab
- President, Chief Executive Officer, Director
- Stephen Brady
- Executive Vice President, Chief Medical Officer, Head of Research and Development
- Samuel Whiting
- Vice President - Finance, Corporate Secretary
- Nicholas Maestas
- Independent Director
- Geoffrey Nichol
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $71.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 22.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.76 |
EPS | $-1.76 |
Book Value | $1.21 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
